SNDL Inc. (Nasdaq: SNDL) began trading on the Canadian Securities Exchange under the symbol SNDL, while maintaining its Nasdaq listing. Meanwhile, IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) said it received word from Nasdaq that it no longer complies with the minimum stockholders’ equity requirement for continued listing, giving the company until May 26 to submit a compliance plan.

SNDL shares were trading up 1.82% at $1.3950 as of Friday morning following the CSE listing announcement, though the stock has struggled with a year-to-date decline of 22.07% and a one-year drop of 33.25%, according to Yahoo Finance data.

“Listing on the CSE enhances SNDL’s structural flexibility and creates optionality for shareholders while reinforcing our commitment to the Canadian market,” SNDL CEO Zach George said in a statement. “As regulated product markets continue to evolve, this listing positions us to pursue growth opportunities with greater agility and alignment to our long-term vision.”

The CSE’s regulatory framework specifically supports cannabis companies with U.S. exposure, according to SNDL, which could open doors for future moves as the company continues scaling. Despite a ever-more crowded national market, SNDL, which also operates as Canada’s largest private-sector liquor and cannabis retailer, says it continues to build its consumer-facing cannabis brands as it searches for strategic capital deployment opportunities throughout North America. Its retail banners including Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf and Superette.

For IM Cannabis, which operates in Israel and Germany, the Nasdaq notification came after the company reported stockholders’ equity of $2.2 million in its annual filing, below the $2.5 million minimum requirement for the Nasdaq Capital Market. The company’s shares were down 0.75% to $1.3299 on Friday, with the stock having declined 42.65% year-to-date and 69.51% over the past year.

IM Cannabis has 45 days, until May 26, to submit a compliance plan, and if accepted by Nasdaq, could receive up to 180 calendar days to regain compliance.

“The company’s business operations are not affected by the receipt of the Notification Letter,” IM Cannabis stated, adding that it is “looking into various options available to regain compliance.”

The company also announced plans to acquire the remaining 26% interest in Focus Medical Herbs Ltd. from Ewave Group Ltd., a privately held entity jointly owned by IMC’s related parties. The purchase would be settled through the issuance of common shares rather than cash to preserve the company’s finances.

Data collection company MoreBetter announced a new study aimed at understanding the impact of THC-infused beverages on alcohol consumption, mood and overall quality of life. The company said it is looking for 2,000 qualified participants to provide daily feedback over three weeks about their infused beverage and alcohol consumption patterns, as well as self-assessments on their overall quality of life.

Infused beverages have become the hottest thing in cannabis. It seems every week, more brands are introducing some form of seltzer or juice infused with either regulated THC or a hemp-based THC. However, there has been little research into the effects or benefits of consuming these products.

Participants in the study must be over the age of 21 and willing to share their day-to-day experiences with using infused beverages. Individuals can check if they’re eligible for the study at this website: mystudi.es/bevstudy.

The study is sponsored by several leading beverage brands, that will collectively supply study participants with free infused beverage products to consume throughout the study.

“By collecting consumer-reported outcomes from thousands of consumers, over a multiweek basis, we provide brands and industry advocates with the real world data they need to understand how infused beverages are impacting consumers’ quality of life,” MoreBetter COO Tyler Dautrich said.

Alcohol sales have been trending downward as interest in about THC-infused beverages has increased. Some of the largest alcohol distributors, such as Total Wine & More and Spec’s, now include large selections of infused beverages. The brands, however, want to gain insight into how consumers are using their products and what perceived lifestyle benefits or wellness outcomes might result after consumption.

“The cannabis plant should be better researched, and we are hopeful that this is just the first step in learning how these products can improve people’s lives as acceptance, access, and consumption of infused beverages expands across the US,” said Adam Terry, CEO of Cantrip, also a sponsor of the study.

The study will mainly focus on canned THC-Infused seltzers, but MoreBetter will also investigate 750ml bottles used as mixers, dry powder mixes and 1.5-2 oz “shots” to study how various doses and form factors impact consumers’ perceived experiences.

“As more consumers explore mindful options, real-world data like this will be essential in understanding how THC-infused beverages are enhancing quality of life and transforming social rituals. Our partnership with MoreBetter isn’t just about validating our brands – it’s about leading a cultural shift with integrity, innovation, and style,” said Evan Eneman, CEO and co-founder of Iconic Tonics.

MindBio Therapeutics Corp. (Frankfurt: WF6) (CSE: MBIO) on Friday announced a new financing package that includes a private placement and substantial debt settlements to help strengthen its cash position.

The company plans to raise up to $170,000 via a non-brokered private placement of 15.45 million common shares priced at $0.011 per share, according to a news release. At the same time, MindBio is working to settle $1.76 million in outstanding debt through the issuance of up to 160 million shares at the same price.

The Vancouver-based firm specializes in microdosing psychedelic medicines for mental health conditions. Its lead candidate, MB22001, is described as a “proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing.”

According to the announcement, MindBio has completed Phase 1 clinical trials in 80 healthy participants and a Phase 2a trial in patients with major depressive disorder, with “positive top line data reported” for both. The company is currently conducting two Phase 2B trials – one in cancer patients experiencing existential distress and another in patients with MDD. It also received approval for multiple Phase 1/Phase 2B trials focused on women’s health.

The private placement is expected to close around April 18, pending approval from the Canadian Securities Exchange. MindBio may pay finder’s fees of up to 8% of the gross proceeds, which could be settled through cash or additional shares at the offering price.

The company noted that the debt settlement arrangements concern “certain unsecured loans and payables that are due and owing.” Insiders may participate in the debt settlement.

The company said it intends to rely on exemptions from formal valuation and minority shareholder approval requirements since “no securities of the Company are listed on specified markets and the fair market value of the debt being settled by interested parties does not exceed 25% of the Company’s market capitalization.”